Healthleap just secured $38 million in fresh funding. The startup builds an AI platform that reads patient records to identify individuals at risk of undiagnosed illnesses.
The financing breaks down into an $8 million seed round and a $30 million Series A. Sequoia Capital and First Round Capital co-led the seed round. Meanwhile, Hummingbird Ventures led the Series A. Healthleap chose not to disclose its current valuation. The company will use the new capital to boost engineering, product development, sales, and customer success.
Announcing $38M Seed & Series A from Sequoia, First Round, and Hummingbird.
Healthleap’s mission is to improve the health outcomes of as many people as possible.
Results so far:
• faster healing resulting in 1.6 shorter hospital stays per patient flagged as at risk by HealthLeap (Penn)
• 39% more appropriate diagnoses, same staff (Cedars-Sinai)
• 3 → 50+ hospitals in the past yearWe’re hiring across all roles.
— Josiah Meyer (@josiahbuild) October 7, 2026
From A Simple Nutrition Tool to An AI Screening Platform
Siblings Jemima and Josiah Meyer founded Healthleap in South Africa in 2022. Originally, Jemima built a clinical nutrition tool for dietitians. Later, the founders pivoted. They transformed the tool into a general-purpose AI screening platform. Josiah currently serves as the CEO.
Healthleap plugs directly into a hospital’s electronic health record (EHR) system. Every night, the AI analyzes adult inpatient records. It processes structured data like lab results, vital signs, diet orders, and medications. Furthermore, the software uses language models to analyze unstructured data. It extracts affirmative or negated mentions of clinical concepts from clinicians’ written notes. For example, it looks for phrases like “poor appetite”, “muscle loss”, or “trouble swallowing”.
Each morning, the system delivers a risk score to the care team’s dashboard. However, the AI does not diagnose patients. It merely flags individuals who need a closer look.
Healthleap Tackling Malnutrition & Delirium
Currently, the AI primarily screens for malnutrition and delirium. Malnutrition is a massive problem in healthcare. Research shows that 20% to 50% of hospital inpatients suffer from malnutrition. Unfortunately, the condition often goes undiagnosed early on. This oversight leads to longer hospital stays, impaired wound healing, infections, and higher mortality rates.
Healthleap offers a clear solution to this blind spot. As a result, the startup has scaled rapidly. Over the past 12 months, Healthleap grew its deployment from three hospitals to over 50. Revenue also jumped 10x during this period. Major clients now include Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist, and Emory Healthcare.
Delivering Hard ROI & Future Expansion
Healthleap sells three-year contracts based on a hospital’s licensed bed count. The company uses an outcome-based pricing model. It ties this pricing to a hard, measurable ROI validated by the hospital’s own finance team. Consequently, Healthleap contractually ensures it delivers multiples of the contract price. All current customers have seen at least a 5x hard ROI. Some hospitals even exceeded a 20x annual return.
The Hospital of the University of Pennsylvania (Penn Medicine) provides a perfect case study. Healthleap’s malnutrition program generated a $23.8 million annualized financial impact for the hospital. Specifically, $6.3 million came from additional reimbursements. The remaining $17.5 million came from savings tied to shorter hospital stays.
Looking ahead, Healthleap wants to expand its capabilities. The AI startup is currently validating programs to identify aspiration pneumonia, pressure ulcers, and congestive heart failure readmission risks. Ultimately, Healthleap plans to cover over 40 major health conditions and expand into outpatient and home care.
